Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Talk outline
3. Pharmacogenetics: vision of the future?
4. Pharmacogenetics and clinical potential
5. Major potential areas of patient benefit
6. Treatment of high blood cholesterol by statins
7. Pharmacogenetics of statin response (1)
8. Pharmacogenetics of statin response (2)
9. Better-than-average response: LDL plasma levels
10. Better-than-average response: inflammation
11. WOSCOPS study
12. Pharmacogenetics - IL6 genotype and CHD risk
13. Better-than-average response: conclusions
14. Pharmacogenetics - pitfalls
15. The REGRESS trial and CETP genotype (1)
16. The REGRESS trial and CETP genotype (2)
17. CETP TaqI meta-analysis
18. CETP TaqI - pravastatin meta-analysis
19. Use of pharmacogenetics to avoid side-effects
20. Warfarin, CYP2C9*3 and avoiding bleeds
21. The TPT trial and bleeds by CYP2C9 genotype
22. Ethical concerns: pharmacogenetics and ethnicity
23. Summary: progress, pitfalls and clinical potential

Topics Covered

• Therapeutic index, genetic variation determining codine and thiopurine metabolism
• Pharmacogenetics and statin response, involvement of HMG co-reductase
• Statin response in patients with FH
• Anti-inflammatory effects of statins and the IL-6 gene
• Pravastatin and CETP genotype
• Initial studies
• Pravastatin and CETP genotype
• Meta-analysis results
• Use of pharmacogenetics to avoid side effects
• Warfarin and CYP2C9 as an example
• Ethical concerns

Links

Series:

• Genetics of Cardiovascular Disease

Categories:

• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Humphries, S. (2008, November 24). Pharmacogenetics: progress, pitfalls and clinical potential [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 30, 2024, from https://doi.org/10.69645/HWLE7854.
Export Citation (RIS)

Publication History

• Published on November 24, 2008
• Archived on February 25, 2021

Financial Disclosures

• Professor Humphries is the Medical Director of StoreGene a UCL spin out company that offers DNA testing for Cardiovascular Disease risk including testing for FH. Professor Humphries is a consultant for Verve Therapeutics, a US based company that is developing gene-editing agents to treat individuals with hypercholesterolaemia, including those with FH.